Coeptis Therapeutics (NASDAQ:ZSQR) Stock Price Down 7% – Here’s Why

Coeptis Therapeutics Holdings, Inc. (NASDAQ:ZSQR)’s share price fell 7% on Monday . The company traded as low as $10.10 and last traded at $10.22. 155,485 shares traded hands during trading, a decline of 23% from the average daily volume of 201,585 shares. The stock had previously closed at $10.99.

Analyst Upgrades and Downgrades

Separately, Wall Street Zen downgraded Coeptis Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, June 13th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock currently has a consensus rating of “Sell”.

Coeptis Therapeutics Stock Performance

The business has a 50 day moving average price of $11.75 and a 200 day moving average price of $12.53. The company has a debt-to-equity ratio of 0.01, a current ratio of 3.25 and a quick ratio of 3.25. The stock has a market capitalization of $436.65 million, a PE ratio of -3.37 and a beta of -0.25.

Coeptis Therapeutics (NASDAQ:ZSQR) last released its quarterly earnings data on Thursday, May 14th. The company reported ($0.65) earnings per share for the quarter. The firm had revenue of $0.11 million for the quarter. Coeptis Therapeutics had a negative net margin of 810.04% and a negative return on equity of 92.29%.

Hedge Funds Weigh In On Coeptis Therapeutics

A number of hedge funds have recently modified their holdings of ZSQR. Steward Partners Investment Advisory LLC grew its position in shares of Coeptis Therapeutics by 100.0% during the fourth quarter. Steward Partners Investment Advisory LLC now owns 5,000 shares of the company’s stock worth $71,000 after purchasing an additional 2,500 shares in the last quarter. Yorkville Advisors Global LP bought a new position in Coeptis Therapeutics in the 3rd quarter worth approximately $140,000. Marshall Wace LLP bought a new position in Coeptis Therapeutics in the 4th quarter worth approximately $259,000. State Street Corp grew its holdings in Coeptis Therapeutics by 35.0% during the 4th quarter. State Street Corp now owns 26,830 shares of the company’s stock valued at $382,000 after buying an additional 6,962 shares in the last quarter. Finally, Geode Capital Management LLC grew its holdings in Coeptis Therapeutics by 12.6% during the 4th quarter. Geode Capital Management LLC now owns 42,097 shares of the company’s stock valued at $600,000 after buying an additional 4,721 shares in the last quarter. 13.88% of the stock is currently owned by institutional investors.

Coeptis Therapeutics Company Profile

Coeptis Therapeutics Holdings, Inc, a biopharmaceutical company, develops cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; SNAP-CAR, a CAR T cell therapy platform co-administered with tagged, tumor-specific antibodies to potentially target different tumor types, including hematological malignancies and solid tumors; and CD38-Diagnostic, an in vitro screening tool to analyze if cancer patients might be appropriate candidates for anti-CD38 mAb therapy.